Skip to content

A Pilot study for Exercise and Nutrition Intervention for Cancer Patients with low muscle mass during chemotherapy

A Pilot study for Mobile Application-based Exercise Intervention and Nutrition Intervention for Cancer Patients with low muscle mass during chemotherapy Nickname: SCONE (sarcopenia intervention for oncology patients with nutrition and exercise)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0009224
Enrollment
30
Registered
2024-03-07
Start date
2024-04-12
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : This is a program that provides exercise intervention using a mobile application and oral nutritional supplement drinks for 12 weeks for patients receiving chemotherapy.

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age 19 or older 2) Patients with histologically confirmed solid cancer 3) Planned or receiving palliative chemotherapy or neoadjuvant/adjuvant chemotherapy using two or more cytotoxic chemotherapy agents 4) ECOG performance status 0-2 5) If a basal abdominal CT (contrast CT must include the portal phase) that can confirm sarcopenia was taken within 4 weeks of participating in the study. 6) Class I or class II sarcopenia with skeletal muscle index (=skeletal muscle area / BMI) T-score less than -1.0 measured by CT 7) Life expectancy of more than 3 months 8) Patients who can understand the research subject consent document and are willing to sign it

Exclusion criteria

Exclusion criteria: 1) Cases where there is a high risk of injury or fall during exercise intervention, such as bone metastasis, peripheral neuropathy, brain metastasis, etc. 2) Cases where it is difficult to follow the exercise intervention of the mobile application due to cognitive decline, illiteracy, or severe hearing and vision impairment. 3) If you do not have a smartphone 4) Cases where protein intake is limited due to decreased renal function (eGFR <50mL/min/1.73m2) 5) When the researcher determines that exercise and nutritional intervention are not best for the patient due to other clinical conditions. 6) Over 80 years old

Design outcomes

Primary

MeasureTime frame
SMI (skeletal muscle index) T-score assessed by CT

Secondary

MeasureTime frame
Myosteatosis index assessed by CT (NAMA/TAMA index T-score) *NAMA (normal-attenuation muscle area), TAMA (total abdominal muscle area);Skeletal muscle mass, fat mass, lean body mass (kg/m2) evaluated by BIA (Bioelectrical Impedance Analysis);Body Mass Index (kg/m2) , Ht, weight, waist circumference;Nutritional assessment using MNA-SF (Mini Nutritional Assessment-Short Form);Exercise evaluation using SPBB (short physical performance battery);Hand grip strength (kg) ;(health-related quality of life; EORTC-QLQ-C30);Compliance to exercise and nutrition interventions (%);Progression-free survival (calculated separately for metastatic and non-metastatic cancer);Overall survival (calculated separately for metastatic and non-metastatic cancer);Blood test results (CRP, LD, CBC, t-chol, albumin); Incidence, nature and severity of adverse events with severity (Safety profile) - Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Countries

Korea, Republic of

Contacts

Public ContactSunyoung Kim

Asan Medical Center

sunyoungkim@amc.seoul.kr+82-2-3010-3204

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Jun 27, 2026